PEDIATRIC ONCOLOGY 

The Stegmaier laboratory is dedicated to the goal of precision pediatric oncology medicine.  We have pioneered the development and application of innovative genomic approaches to better understand the mechanisms underlying childhood cancers and to identify the next generation of therapies. Our lab has discovered novel technologies, concepts, and targets and has advanced new biomarkers and therapies to the clinic for patients with cancer. Specifically, our research program focuses on the integration of functional genomic and chemical biology approaches toward the identification of new protein targets and small-molecule modulators of pediatric malignancies. We study pediatric malignancies with few recurrent point mutations but notable for aberrancies of differentiation and/or oncogenic activation of transcription factors (e.g., fusion oncoproteins), such as leukemias, sarcomas, and neuroblastoma. Our team is highly collaborative and draws on the expertise of cancer biologists, computational biologists, chemists, structural biologists, and translational researchers.
​

---